Bauer J H
Arch Intern Med. 1983 Jun;143(6):1163-7.
Guanabenz acetate is a new centrally acting alpha 2-adrenergic agonist. Seventeen hypertensive men, in whom BP was normalized with guanabenz, underwent assessment of renal function, renal hemodynamics, and body fluid composition following short-term (three to six weeks), long-term (five to six months), and withdrawal (two weeks) therapy. Guanabenz therapy caused a modest but reversible reduction in glomerular filtration rate (12% to 18%), effective renal plasma flow (9% to 17%), and renal blood flow (12% to 20%). Renal vascular resistance was unchanged. Guanabenz therapy had no significant natriuretic or antinatriuretic effects in patients with an effective BP decrease, although it had the ability to produce and sustain a water diuresis. Guanabenz therapy was not associated with salt and water increases within body fluid compartments. Guanabenz, in some patients, is an effective monotherapy for the treatment of hypertension.
醋酸胍那苄是一种新型的中枢性α₂肾上腺素能激动剂。17名使用胍那苄使血压恢复正常的高血压男性患者,在接受短期(三至六周)、长期(五至六个月)及撤药(两周)治疗后,接受了肾功能、肾血流动力学及体液成分的评估。胍那苄治疗使肾小球滤过率适度但可逆地降低(12%至18%),有效肾血浆流量降低(9%至17%),肾血流量降低(12%至20%)。肾血管阻力未改变。在血压有效降低的患者中,胍那苄治疗对利钠或抗利钠无显著影响,尽管它有产生并维持水利尿的能力。胍那苄治疗与体液 compartments 内盐和水的增加无关。在一些患者中,胍那苄是治疗高血压的一种有效单一疗法。